Swedish Orphan Biovitrum AB reports Q2 results
- BySeeking Alpha-
Swedish Orphan Biovitrum AB (BIOVF): Q1 GAAP EPS of SEK2.36.Revenue of SEK3.66B (-21.1% Y/Y)Press Release
Swedish Orphan Biovitrum AB (BIOVF): Q4 GAAP EPS of SEK5.09.Revenue of SEK4.58B (-6.3% Y/Y).Press Release
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q4 earnings call.
One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (EXEL), developer of the compound cabozantinib. Cabo, which was FDA...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Neutral | Buy | Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | NASDAQ | |||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | NASDAQ | |||
| 232.88 | 234.12 | 232.10 | +0.64 | +0.28% | 1.11M | NYSE | |||
| 20.95 | 21.38 | 20.57 | -0.26 | -1.23% | 158.34K | NASDAQ | |||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | NASDAQ | |||
| 206.53 | 206.89 | 203.56 | -7.51 | -3.51% | 25.54M | NYSE | |||
| 41.68 | 41.83 | 41.42 | +0.21 | +0.51% | 21.61M | NYSE | |||
| 12.39 | 12.53 | 11.62 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 12.85 | 12.995 | 12.775 | 0.000 | 0.00% | 0.00 | OTC Markets | |||
| 192.18 | 193.25 | 189.69 | +2.22 | +1.17% | 528.47K | NASDAQ | |||
| 11.41 | 11.61 | 11.19 | -0.22 | -1.89% | 1.78M | NYSE | |||
| 23.47 | 24.49 | 22.70 | -1.40 | -5.63% | 1.21M | NASDAQ | |||
| 299.25 | 299.98 | 296.99 | +1.74 | +0.58% | 361.16K | NYSE | |||
| 150.64 | 152.84 | 150.25 | -0.29 | -0.19% | 9.67M | NYSE | |||
| 9.70 | 9.99 | 9.47 | -0.20 | -2.02% | 1.57M | NYSE |
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.